Viking Therapeutics Grants Equity Package to New Commercial Chief Amid Key Clinical Milestones

Viking Therapeutics has filed a mandatory disclosure with the U.S. Securities and Exchange Commission (SEC) detailing the compensation package for its newly appointed Chief Commercial Officer, Neil William Aubuchon. The filing centers on a substantial stock option award designed to align the executive’s interests with the company’s long-term performance. This administrative update arrives during a period of significant clinical development activity for Viking’s lead obesity drug candidate, VK2735.

The compensation disclosure follows two important clinical updates from Viking Therapeutics early in the year. The biopharmaceutical company, which currently derives its value from its development pipeline, is advancing VK2735, a dual GLP-1 and GIP receptor agonist for weight Read more...